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The natural history of cancers associated with virus exposure is intriguing, since only a minority of human tissues infected
with these viruses inevitably progress to cancer. However, the molecular reasons why the infection is controlled or instead
progresses to subsequent stages of tumorigenesis are largely unknown. In this article, we provide the first complete DNA
methylomes of double-stranded DNA viruses associated with human cancer that might provide important clues to help us
understand the described process. Using bisulfite genomic sequencing of multiple clones, we have obtained the DNA
methylation status of every CpG dinucleotide in the genome of the Human Papilloma Viruses 16 and 18 and Human
Hepatitis B Virus, and in all the transcription start sites of the Epstein-Barr Virus. These viruses are associated with
infectious diseases (such as hepatitis B and infectious mononucleosis) and the development of human tumors (cervical,
hepatic, and nasopharyngeal cancers, and lymphoma), and are responsible for 1 million deaths worldwide every year. The
DNA methylomes presented provide evidence of the dynamic nature of the epigenome in contrast to the genome. We
observed that the DNA methylome of these viruses evolves from an unmethylated to a highly methylated genome in
association with the progression of the disease, from asymptomatic healthy carriers, through chronically infected tissues
and pre-malignant lesions, to the full-blown invasive tumor. The observed DNA methylation changes have a major
functional impact on the biological behavior of the viruses.
[Supplemental material is available online at www.genome.org. Viral DNA methylomes are freely available for viewing at
http://ubio.bioinfo.cnio.es/Methylyzer/main/index.html.]
Epigenetics encompasses a large number of mechanisms un-
derlying embryonic development, differentiation, and cell iden-
tity including DNA methylation and histone modifications and is
increasingly recognized as being involved in human diseases such
as cancer and imprinting disorders, among others (Bernstein et al.
2007; Esteller 2007; Feinberg 2007; Jirtle and Skinner 2007; Jones
and Baylin 2007). For the first time, it is possible to define whole
epigenomes, which represent all epigenetic marks in a given cell
type, thanks to the development of new powerful genomic tech-
nologies (Bernstein et al. 2007; Esteller 2007; Feinberg 2007; Jirtle
and Skinner 2007; Jones and Baylin 2007). In contrast to the hu-
man genome, human epigenomes vary between tissues, among
individuals, and between healthy and disease states. Under these
circumstances, distinct epigenomes might explain why the same
genotypes generate different phenotypes as occurs in the Agouti
mice (Michaud et al. 1994), cloned animals (Humpherys et al.
2001), and monozygotic twins (Fraga et al. 2005).
Determining the complete DNA methylome entails the de-
scription of all the methylated nucleotides in an organism. The
gold standard technique for analyzing the methylation state of
individual cytosines is bisulfite sequencing in which unmethy-
lated cytosines are converted to uracils and read as thymines,
while methylated cytosines are protected from conversion. Bi-
sulfite sequencing yields precise nucleotide resolution data, but to
date, this method has been limited to relatively small genome
coverage (Rakyan et al. 2004; Eckhardt et al. 2006; Frigola et al.
2006). Alternative approaches involve the isolation of methylated
fractions of the genome by methylation-sensitive restriction
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(Lippman et al. 2005), or immunoprecipitation with a methyl-
cytosine-specific antibody (Weber et al. 2005, 2007; Keshet et al.
2006), combined with hybridization to genomic microarrays. This
is exemplified by the recent DNA methylation analyses of the
Arabidopsis genome (Zhang et al. 2006; Vaughn et al. 2007;
Zilberman et al. 2007), further expanded by using sequencing-
by-synthesis technology (Lister et al. 2008). We decided to com-
bine these latter two approaches, extensive analyses of DNA
methylation by bisulfite genomic sequencing of multiple clones and
the use of model organisms, to obtain the complete DNA methyl-
omes of double-stranded DNA viruses associated with human can-
cer. The chosen option recalls the U.S. Department of Energy’s
establishment in 1994 of the Microbial Genome Program (MGP) as
a companion to its Human Genome Program. From the very start,
the MGP achieved remarkable success, and microbial genomics has
become one of the most exciting and high-profile fields in biology
today. Thus, the complete description of the DNA methylomes of
model organisms, such as double-stranded DNA viruses, might have
anenormous impacton thesuccessof thehuman epigenome project
(Jones and Martienssen 2005; Brena et al. 2006).
Worldwide, it has been estimated that viral infections are
etiologically linked to 15% of cancer cases, accounting for nearly
1.5 million new cases and 1 million deaths annually (Butel 2000;
Gatza et al. 2005). Three well-studied oncogenic viruses are the
human papilloma virus (HPV) (Papillomaviridae; Alphapapillomavirus;
Human Papillomavirus), the hepatitis B virus (HBV) (Hepadnavir-
idae; Orthohepadnavirus; Hepatitis B virus), and the Epstein-Barr
Virus (EBV) (Herpesviridae; Gammaherpesvirinae; Lymphocryptovirus;
Human Herpesvirus 4). All of these are double-stranded DNA
viruses, which are not only involved in the development of in-
fectious diseases (such as infectious mononucleosis and hepatitis),
but also in the formation of cervical, liver, and nasopharyngeal
tumors and lymphomas, respectively (Butel 2000; Gatza et al.
2005). It is known that DNA methylation is present in some of
these viral sequences—for example, in HPV16 (Thain et al. 1996;
Kim et al. 2003) and EBV (Ambinder et al. 1999; Minarovits
2006)—but the complete coverage of their genomes and the bi-
ological consequences have not been systematically addressed.
Herein, we present the complete DNA methylomes of the HPV16,
HPV18, and HBV viruses and the DNA methylation analyses of all
the transcription start sites of EBV obtained by bisulfite genomic
sequencing of multiple clones. We also analyze the dynamic
changes in the viral DNA methylome and their functional rele-
vance in the natural history of the disease.
Results
The DNA methylome of HPV16
There are more than 100 different papilloma family members,
and, in humans, these are responsible for a variety of benign
proliferations. However, infection with two specific high-risk
HPVs—HPV-16 and HPV-18—is associated with ;90% of uterine
cervical cancers, >50% of other anogenital tumors, and a small
percentage of head and neck tumors (zur Hausen 2002). HPV
particles consist of circular DNA molecules, »8000 bp long,
wrapped into a protein shell that is composed of two molecules
(L1 and L2). The genome has the coding capacity for these two
proteins and at least six so-called early proteins (E1, E2, E4–E7)
that are necessary for the replication of the viral DNA and for the
assembly of newly produced virus particles within the infected
cells. Both sets of genes are separated by an upstream regulatory
region (URR) of ;1000 bp that does not code for proteins but
contains cis-elements required for regulation of gene expression,
replication of the genome, and its packaging into virus particles
(Butel 2000; zur Hausen 2002; Gatza et al. 2005). Two of the viral
proteins—E6 and E7—are essential for HPV-mediated cellular
transformation (Wise-Draper and Wells 2008). These interfere
with many cellular processes, overriding signaling pathways and
cell cycle control by altering the function of basal transcription
factors TP53 (also known as p53) and RB1 (also known as Rb),
among other target proteins (Wise-Draper and Wells 2008).
The natural history of the disease is intriguing, since only
a minority of cervical tissues infected with HPV inevitably progress
to cancer. Given that around 291 million women throughout the
world are carriers of HPV DNA (de Sanjose et al. 2007), the in-
cidence of cervical cancer is relatively low (zur Hausen 2002).
Thus, the development of cervical cancer occurs in a few women
who cannot resolve their infection and who maintain persistent
active infection for years or decades following initial exposure.
However, the molecular reasons why the infection is controlled or
instead progresses to subsequent stages of tumorigenesis are
largely unknown. The complete HPV DNA methylomes obtained
in our study might provide important clues to help us understand
the described process.
First, we sequence the whole DNA methylome of the HPV16
virus (110 CpGs in 7904 nt) in a collection of human cervical
samples corresponding to the different progressive stages of the
disease: asymptomatic carriers (n = 5), pre-malignant disease (the
so-called Cervical Intraepithelial Neoplasia, CIN; n = 8), and the
primary cervical carcinomas (n = 5). We have also completed the
HPV16 DNA methylome of four established cervical cancer cell
lines (CaSki, SiHa, CCL-866, and CLL-879). We discovered that the
HPV16 DNA methylome undergoes a progressive increase in its
DNA methylation content from tissue of women who are carriers
of the virus but without any symptom of clinical disease, through
early pre-tumorigenic lesions, to full-blown primary cervical car-
cinomas (Fig. 1A). In this sequence of events, the HPV16 DNA
methylomes of the invasive cervical cancer cell lines CaSki and
SiHa are the ones demonstrating the higher DNA methylation
levels. We developed an unsupervised clustering analysis for the
18 HPV16 DNA methylomes obtained that also distinguished the
four different biological groups: carriers, pre-malignancies, pri-
mary tumors, and cancer cell lines (Fig. 1A). The DNA methylation
patterns and deletions of the HPV genomes are both responsible in
the establishment of the clustering. Examples of the bisulfite ge-
nomic sequencing analysis of multiple clones of the HPV16 virus
genome are shown in Figure 1B. To examine the HPV16 DNA
methylomes, please go to http://ubio.bioinfo.cnio.es/Methylyzer/
main/index.html.
The dynamic changes experienced by the viral DNA meth-
ylome during the tumorigenic process were highlighted when we
studied cultured primary human foreskin keratinocytes trans-
fected with the entire genome of HPV16 that integrates in the host
genome (Steenbergen et al. 1996; Van Tine et al. 2004). The HPV16
DNA methylome from the pre-immortal keratinocytes was almost
completely unmethylated, while the immortal descendant cells
featured a densely methylated viral genome (Fig. 1C). Most im-
portantly, genetic changes in the HPV16 genome were not ob-
served. This observation was a universal feature of our studies:
Because our DNA methylation analysis by bisulfite genomic se-
quencing also allows putative nucleotide changes (such as point
mutations, insertions, or deletions) to be identified, we were able
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itself to the progression of the disease (with the exception of T or C
nucleotide changes that could be caused by failed bisulfite con-
version). We did not observe any particular viral nucleotide
change associated with the natural history of cervical tumori-
genesis.
The HPV16 genome does not code for any gene of the DNA
methylation machinery, such as DNA methyltransferases
(DNMTs). Thus, the viral genome is methylated by the host hu-
man cellular DNMTs. The integration of HPV16 in the human
genome occurs in most cervical tumors and a significant pro-
portion of pre-malignant lesions, and so it is reasonable to suggest
that human DNMTs might methylate these sequences (Bernstein
et al. 2007; Esteller 2007; Feinberg 2007; Jirtle and Skinner 2007;
Jones and Baylin 2007). A list of the known integration sites for
the studied viral genomes is provided in Supplemental Table S1.
Indeed, in our study, we have confirmed by FISH analysis that the
HPV16 genome is integrated within the host cell DNA in CaSki
and SiHa cells (Supplemental Fig. S1). A correlation between
a higher number of integrated copies and a higher DNA methyl-
ation level might exist, and it could be the focus of future research
in the area. A list of the known copy numbers for the studied viral
genomes is provided in Supplemental Table S2. Most importantly,
confocal studies demonstrated the colocalization of the integrated
viral genome and 5-methylcytosine DNA staining (Fig. 1D). The
use of a DNA demethylating agent (5-aza-29-deoxycytidine) in
CaSki cells did, indeed, cause DNA hypomethylation of the HPV16
genome (Fig. 1E). Interestingly, the HPV16 genome is not merely
a passive spectator of the process but might actively participate by
recruiting DNMTs using the viral oncoprotein E7 (Burgers et al.
2007).
The HPV16 DNA methylomes described here also reflect the
proposed expression patterns of the virus in cervical tumorigene-
sis, which are characterized by a significant overexpression of E6
and E7 in the carcinomas (Butel 2000; zur Hausen 2002; Gatza
et al. 2005; Wise-Draper and Wells 2008). Our sequencing effort
shows that, for a subset of cases spanning the range of stages, there
are genomic viral regions that are deleted, particularly the E1/E2
region. The protein E2 inhibits cell proliferation by regulating the
viral upstream regulatory region (URR), repressing the E6 and E7
oncoproteins, and, ultimately, causing cell cycle arrest at G2
(Frattini et al. 1997). Thus, the genomic loss of E2 could contribute
to the progression of the disease. However, the HPV16 DNA
methylomes described here show that there are many cases in
which there are not any ruptures at the E2 locus, and, accordingly,
E2 is expressed (Fig. 1F). We observed instead methylation of the
E2-binding sites at the URR region (Fig. 1A,F) that was associated
with a high level of expression of the oncoproteins E6 and E7 (Fig.
1F). Most importantly, we showed by chromatin immunoprecip-
itation (ChIP) that the E2 viral protein could not bind to the
methylated E2-binding sites at the URR region (Fig. 1F), and thus
led to E6 and E7 overexpression. Finally, the induction of hypo-
methylation events in the E2-binding sites at the URR region by
a DNA demethylating agent (5-aza-29-deoxycytidine) induced the
recruitment of E2 to its URR-binding sites and a marked reduction
of E6 and E7 expression (Fig. 1F). Most important, methylation of
the E2-binding sites at the URR region was observed in six of eight
(75%) primary cervical tumors that did not present E2 genomic
deletion (Fig. 1G). Thus, our in vivo findings support the in vitro
data about the inhibition of E2 binding to CpG methylated E2-
binding sites at the URR (Thain et al. 1996).
We went one step further to confirm these results in a large
collection (n = 99) of human primary samples from the different
stages of cervical carcinogenesis. Once we have discarded those
cervical tumors with L2 deletions (n = 12), we conducted in the
remaining samples (n = 87), the technique of methylation-specific
PCR to analyze the L2 and L1 DNA methylation status (Fig. 1G).
We observed the progressive presence of hypermethylation at the
L2 locus in tumorigenesis: 0% (0 of 10) in asymptomatic carriers,
29% (five of 17) in stage I of intraepithelial neoplasia (CIN I), 37%
(16 of 43) in stages II and III of intraepithelial neoplasia (CIN II–
III), and 94% (16 of 17) in primary cervical carcinoma. L1 meth-
ylation was analyzed in a subset of these cases (n = 14), and it was
always concordant with L2 methylation. Overall, the DNA
methylomes of HPV16 outlined are evidence of the existence of an
adaptive DNA methylation pattern of the viral genome, whereby
there was an increased methylated-CpG content during the pro-
gression of the disease arising from the cross-talk between the viral
and the host genomes.
The DNA methylome of HPV18
HPV16 is the most prevalent high-risk papilloma virus in the
general population and is responsible for ;50% of cervical can-
cers, but HPV18 occupies second place in both instances. HPV16
and HP18 are representative of two different HPV species (alpha9
and alpha7, respectively), but share a global genomic structure
that codes for almost identical proteins (Butel 2000; zur Hausen
2002; Gatza et al. 2005; Wise-Draper and Wells 2008). Most im-
portantly, a highly similar pattern was encountered when we
obtained the complete DNA methylomes of the HPV18 virus. The
bisulfite genomic sequencing of the entire HPV18 viral genome
(168 CpGs in 7857 nt) obtained from asymptomatic carriers of the
virus demonstrated a low level of methylation, while an increased
methylated genome was observed in primary cervical carcinomas
(Fig. 2A). The unsupervised clustering analysis was also able to
distinguish infected tissues without clinical relevance from the
full-blown tumors on the basis of the HPV18 DNA methylomes
(Fig. 2A). Examples of the bisulfite genomic sequencing of multi-
ple clones are shown in Figure 2B. The HPV18 DNA methylomes
may be examined at http://ubio.bioinfo.cnio.es/Methylyzer/
Figure 1. The DNA methylome of HPV16. (A) Unsupervised clustering analysis of the HPV16 DNA methylome in asymptomatic carriers of the virus, pre-
malignant lesions (CIN), primary tumors (SCCs), and cancer cell lines (CaSki, SiHA, CCL-879, and CCL-866). (Red) Methylated, (green) unmethylated,
and (black) deleted sequences. (Top) The HPV16 genome. (B) Example of bisulfite genomic sequencing analysis of multiple clones for the HPV16 genome.
(Black squares) Methylated and (white squares) unmethylated CpG dinucleotides; (gray squares) deleted genome sequences. (C) Bisulfite sequencing
showing how the mostly unmethylated HPV16 DNA methylome from pre-immortal keratinocytes undergo hypermethylation in immortalized cells. (D)
Confocal studies for fluorescence in situ hybridization for HPV16 and 5-methylcytosine DNA staining demonstrate the colocalization of the integrated
viral genome in a human chromosome and the DNA methylation signal in CaSki cells. (E) The use of a DNA demethylating agent in CaSki cells causes DNA
hypomethylation of the HPV16 genome. (F) The expression of HPV16 E6 and E7 oncoproteins is associated with a loss of binding of the E2 repressor to the
URR methylated sites. (Top left) The expression of E2 and the methylated status of the URR binding site in CaSki. (Top right) DNA demethylating treatment
reduces E6 and E7 expression in Western blot and (bottom left) qRT-PCT in association with a recruitment of the E2 protein to the demethylated URR E2-
binding site, (bottom right) shown by q-ChIP. (G) Methylation-specific PCR analysis of the HPV16 L2, L1, and URR sequences in cervical tumorigenesis. The
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main/index.html. We not only analyzed the static nature of these
DNA methylomes at given stages, but, as we did with HPV16, also
obtained the HPV18 DNA methylomes present during the im-
mortalization crisis that keratinocytes transfected with the
entire HPV18 genome (integrated in the host genome) undergo
(Steenbergen et al. 1996; Van Tine et al. 2004). The HPV18 DNA
methylome from the pre-immortal keratinocytes was mostly
unmethylated, whereas the immortal cells presented a densely
methylated viral genome (Fig. 2C). Most importantly, no genetic
or nucleotide changes in the HPV18 genome were observed. The
HPV18 genome does not encode for any DNMTs, thus it is believed
to ‘‘use’’ the host enzymes. Short interference RNA depletion of
DNMT1 and DNMT3B did, indeed, induce hypomethylation
events in the HPV18 positive cervical cancer cell line HeLa (Fig.
2D). Although HPV16 and HPV18 share many features in their
DNA methylomes, one interesting distinction occurs for the viral
oncoprotein expression standpoint. The levels of E6 and E7 ex-
pression in HPV18-infected cervical cancer cell lines, such as HeLa
and C4I, were not modified by the treatment with a DNA deme-
thylating agent (Fig. 2E). These findings fit perfectly well with the
observation that the E2-binding sites at the URR region of HPV18
in these cells were not methylated (Fig. 2A,E), and thus the E2-
mediated control of E6 and E7 expression could not be released by
the DNA hypomethylating drug. The presence of DNA methylation
at the E2-binding site of the URR region of HPV16, that drives the
E6 and E7 expression, and its absence in HPV18, might be another
factor that could explain the different prevalence and carcinoge-
nicity of both strains.
Finally, to extend our analysis to a larger collection (n = 32) of
human primary samples from the different stages of HPV18-me-
diated cervical carcinogenesis, we used the technique of methyl-
ation-specific PCR for the E2 region of the virus (Fig. 2F). We
confirmed the progressive presence of hypermethylation at the E2
locus in tumorigenesis: 0% (0 of 6) in asymptomatic carriers, 14%
(one of seven) in stage I of cervical intraepithelial neoplasia (CIN
I), 67% (six of nine) in stages II and III of cervical intraepithelial
neoplasia (CIN II–III), and 90% (nine of 10) in primary cervical
carcinoma.
The DNA methylome of HBV
The third genome whose complete DNA methylome we obtained
is the Hepatitis B Virus (HBV). The HBV infectious virion has an
outer envelope, formed by the hepatitis B surface antigen (HBsAg)
in a lipid bilayer. This encloses the nucleocapsid core, within
which lies the viral genome (Gatza et al. 2005; Lupberger and Hildt
2007). The latter is a relaxed circular, partially double-stranded
DNA molecule of 3215 bp in length and contains four partially
overlapping open reading frames (ORFs). These code for the en-
velope glycoproteins (L, M, and S HBsAgs), the pre-core/core
(precursor of the soluble hepatitis B e antigen, HBeAg, and the core
protein), the X protein (HBx), and the polymerase, which acts as
reverse transcriptase and also has DNA polymerase activity (Gatza
et al. 2005; Lupberger and Hildt 2007). It is interesting that while
HBV is a DNA virus, it replicates through an RNA intermediate and
thus requires the described active viral reverse transcriptase poly-
merase enzyme. HBV infects more than 2 billion people world-
wide, 400 million of which are chronically infected and are at high
risk for the development of active hepatitis, cirrhosis, and hep-
atocarcinoma (HCC) (Gatza et al. 2005; Lupberger and Hildt
2007). The HBV carriers with chronic liver disease have 100-fold
greater risk of developing HCC, which is the third leading cause of
cancer death in the world (Gatza et al. 2005; Lupberger and Hildt
2007). Ninety percent of HBV-associated liver cancers show in-
tegration of the HBV genome within the human genome (Gatza
et al. 2005; Lupberger and Hildt 2007). Two major HBV-specific
mechanisms contribute to the development of HCC: The viral
genome integration in the human genome causes cis-effects that
inactivate tumor-suppressor genes and activate oncogenes; and
the expression of trans-activating factors derived from the HBV
genome, such as the HBx protein and the PreS2 activators
(Schluter et al. 1994), which disrupt the signal transduction
pathways and alter the gene expression of the host cell (Gatza et al.
2005; Lupberger and Hildt 2007).
We completed the HBV DNA methylomes (n = 32) from
different stages of the liver tumorigenesis, from chronic active
hepatitis (CAH) and hepatic cirrhosis (HC) to primary hep-
atocarcinomas (HCCs) and a well-characterized panel of hepatic
cancer cell lines. The samples included genotypes D and A of HBV
(Supplemental Table S3). The results are in concordance with
those observed for HPV16 and HPV18: The HBV genome is almost
completely unmethylated in the early stages of carcinogenesis,
such as hepatitis and cirrhosis, while it becomes more methylated
in the established liver tumors, both in patients and in cultured
cancer cell lines (Fig. 3A). Unsupervised clustering analysis was also
able to classify these liver samples as pre-malignant or malignant
stages on the basis of their HBV DNA methylomes (Fig. 3A). The
DNA methylation patterns and deletions of the HBV genomes are
both responsible in the establishment of the clustering. The HBV
DNA methylomes may be examined at http://ubio.bioinfo.cnio.es/
Methylyzer/main/index.html. Examples of the bisulfite genomic
sequencing of multiple clones are shown in Figure 3B. Most im-
portantly, the presence of DNA methylation at the HBVgp4 and
HBVgp2 genes, which, respectively, code for the C and S viral pro-
teins, is associated with their lack of expression (Fig. 3C), while
release of transcriptional silencing can be achieved by the use of
a DNA demethylating agent (Fig. 3C).
Our sequencing data also show that most of the HBV
genomes, although more methylated than the pre-malignant
lesions, retained the HBVgp3 gene that codes for the X protein
(HB-X) in an unmethylated state (Fig. 3C). HB-X was transcribed
in all the studied liver cancer cell lines (Fig. 3C). Interestingly, the
HB-X protein might regulate DNMT activity (Park et al. 2007). In
this regard, double depletion of DNMT1 and DNMT3B by short
interference RNA in HA22T cells did, indeed, cause DNA hypo-
methylation of the HBV genome (Fig. 3D). Our extensive bisulfite
genomic sequencing effort also established that the integrated
HBV genome undergoes significant deletions, as previously
reported (Gatza et al. 2005; Lupberger and Hildt 2007), which are
more common in CAH and HC than in liver tumors. We de-
veloped a FISH analysis for the HBV virus to demonstrate further
its presence in the liver tumors (Supplemental Fig. S2). Finally, to
expand our study of the HBV DNA methylome and to confirm its
dynamic nature, we tested a larger collection (n = 35) of human
primary samples from the different stages of HBV-mediated liver
carcinogenesis, using the technique of methylation-specific PCR
for the HBVgp2 gene of the virus (Fig. 3E). We have confirmed the
progressive presence of hypermethylation at the HBVgp2 locus in
the hepatic tumorigenesis: 0% (zero of five) in HC, 11% (one of
nine) in CAH, and 52% (11 of 21) in primary liver tumors.
Thus, these data suggest that DNA methylation of the HBV
genome may ‘‘mark’’ those cells that progress toward tumorigen-
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The DNA methylome of EBV
The final extensive DNA methylation of a viral genome we ana-
lyzed in the present study is that of the Epstein-Barr virus (EBV),
which is several orders of magnitude larger than those considered
above (171,823 bp). EBV was discovered more than 40 yr ago ex-
amining cells cultured from Burkitt’s lymphoma, a childhood tu-
mor that is common in sub-Saharan Africa. However, instead of
showing a restricted distribution, EBV has been found to be
widespread in all human populations. Ninety percent of the
world’s adult population is infected by the virus, and it persists in
the vast majority of individuals as a lifelong, asymptomatic in-
fection of the B-lymphocyte cells (Young and Rickinson 2004;
Gatza et al. 2005; Williams and Crawford 2006; Klein et al. 2007),
but can occasionally evolve to an infectious mononucleosis (IM).
In immunocompromised humans, such as AIDS and post-trans-
plant patients, EBV infection is implicated in the etiology of sev-
eral different lymphoid and epithelial malignancies, such as
nasopharyngeal carcinoma (Young and Rickinson 2004; Gatza
et al. 2005; Williams and Crawford 2006; Klein et al. 2007). There
are two alternative states of EBV infection: lytic and latent. Virions
are only produced in lytic infection, and its genome remains as an
episome in the host cell (Young and Rickinson 2004; Gatza et al.
2005; Williams and Crawford 2006; Klein et al. 2007). EBV has the
ability to transform resting B-cells into permanently infected
lymphoblastoid cell lines that constitutively express a limited set
of viral products, which are called ‘‘latent proteins.’’ These onco-
genic genes are the nuclear antigens EBNAs 1, 2, 3A, 3B, 3C, and
LP; and the latent membrane proteins LMPs 1, 2A, and 2B. Other
gene products are the immediate early genes (which are consid-
ered the switch between latent and lytic cycle), the early genes
(e.g., enzymes influencing the host cell nucleotide metabolism
and DNA synthesis), and the late gene products (e.g., the virion
structural proteins) (Young and Rickinson 2004; Gatza et al. 2005;
Williams and Crawford 2006; Klein et al. 2007).
The large EBV genome, of almost 172 kb, prevented us from
deriving the entire EBV DNA methylome using the same technol-
ogy we had used for the HPV16, HPV18, and HBV genomes. In-
stead, we undertook the most extensive DNA methylation analysis
of the EBV genome to date using bisulfite genomic sequencing
analysis of multiple clones for 77 amplicons that contains the
transcription start sites that code for the 94 EBV proteins and the
two structural RNAs, EBER1 and EBER2. The complete set of EBV
transcription start sites studied included 95% (72 of 76) CpG islands
(Takai and Jones 2003) and covered 1344 CpGs of the EBV genome.
Overall, 22 EBV DNA methylomes were obtained from a collection
of lymphoid samples that included benign proliferating cells, such
as reactive lymphadenitis and infectious mononucleosis, non-tu-
morigenic lymphoblastoid cell lines, post-transplant lymphoproli-
ferative disorder, and EBV-associated lymphomas from primary
tissues and cell lines, such as non-Hodgkin lymphoma (diffuse large
B-cell lymphoma and peripheral T-cell lymphoma), Hodgkin lym-
phoma, and Burkitt’s lymphoma. All the samples corresponded to
EBV type A (Supplemental Table S3). In addition, EBV-positive na-
sopharyngeal tumors were also included.
We observed a similar EBV DNA methylation profile to that
observed for HPV16, HPV18, and HBV. The EBV DNA obtained
from free viral particles is devoid of DNA methylation (Fig. 4A);
however, the EBV genome present in human cells corresponding
to benign diseases, such as reactive lymphadenitis in tonsils and
infectious mononucleosis, showed the incipient presence of meth-
ylated EBV transcription start sites (Fig. 4A). The same occasional
hypermethylation was observed in non-tumorigenic human
B-cell-derived lymphoblastoid cell lines (Fig. 4A). Remarkably, this
pattern was significantly changed in cancer cells infected with EBV,
where the majority of lymphoma and nasopharyngeal samples
from primary tumors and cell lines had a large number of hyper-
methylated EBV transcription start sites (Fig. 4A). Unsupervised
clustering analysis was able to distinguish free virus DNA, EBV-
related benign conditions, and EBV-associated human lymphomas
and epithelial carcinomas on the basis of the EBV DNA methylome
(Fig. 4A). These results were confirmed by methylation-specific
PCR in a second set of EBV-positive non-tumorigenic (n = 16)
versus EBV-lymphoma (n = 21) cell lines: Lymphoblastoid cell lines
did not present promoter hypermethylation of Wp and Cp genes,
while Burkitt’s lymphoma cell lines had 43% and 23% hyper-
methylation frequencies, respectively (Fig. 4B). Confocal studies
demonstrated the colocalization of the EBV viral genome de-
termined by FISH (Supplemental Fig. S3) and the 5-methylcytosine
DNA staining in Burkitt’s lymphoma cells (Fig. 4C). The EBV DNA
methylomes may be examined at http://ubio.bioinfo.cnio.es/
Methylyzer/main/index.html.
Interestingly, of the 77 transcription start site regions that
originate the entire EBV mRNA transcriptome, five amplicons
‘‘escaped’’ the DNA methylation mark: the two structural RNAs,
EBER1 and EBER2, and the Qp, BZLF1, and LMP-2B/LMP-1
sequences (Fig. 4A). Methylation-specific PCR analyses for the Qp
sequence confirmed the absence of DNA methylation from the
additional set of both lymphoblastoid (n = 16) and Burkitt’s lym-
phoma (n = 21) cell lines (Fig. 4B). RT-PCR expression confirmed
that the always unmethylated EBER1 was expressed in all the an-
alyzed samples (Fig. 4D). Most importantly, the presence of
a hypermethylated EBV transcription start site in the cancer cells
was associated with the corresponding transcriptional silencing of
the neighboring gene. We demonstrated this close association
between a methylated transcription start site and its loss of tran-
scription at the single gene level, using RT-PCR and Western
blotting (Fig. 4D) for the EBNA2, BRLF1, and BHRF1 genes, and at
the global level, matching the obtained EBV methylomes with our
previous study of the EBV transcriptome by expression micro-
arrays (Supplemental Fig. S4; Yuan et al. 2006). Notably, as it has
also been shown in human cells (Saito et al. 2006; Lujambio et al.
2007), the presence of DNA methylation in a microRNA locus was
also associated with its loss of expression. This was the case for
miR-BHRF1-1, located in the 59-untranslated region of the BHFR1
gene (Pfeffer et al. 2004), which was hypermethylated in Akata
cells (Fig. 4D). The link between DNA methylation and silencing
was further reinforced by the use of the DNA demethylating agent
5-aza-29-deoxycytidine, which was able to restore the expression
of the EBV methylation-inactivated genes and of miR-BHRF1-1
(Fig. 4D).
The EBV genome could be a target of the human DNMTs. In
the case of EBV, we have a research avenue that has been provided
by nature itself. Some individuals are born with a germline defect
in DNMT3B (Immunodeficiency, Centromere Instability, Facial
Anomalies syndrome, ICF, OMIM #242860) (Okano et al. 1999; Xu
et al. 1999), and lymphocytes immortalized with EBV from these
patients have been widely used to understand the DNA methyla-
tion machinery (Matarazzo et al. 2007; Jin et al. 2008). The anal-
ysis of DNA methylation of EBV-immortalized ICF lymphocytes
revealed a more hypomethylated EBV genome than that observed
in DNMT3B-proficient EBV-transformed lymphocytes (Fig. 4E),
which is evidence of the role of DNMT3B in establishing the EBV
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with HPV16, HPV18, and EBV, there may be a cross-talk between
the EBV-viral proteins and the DNA methyltransferases of the host
human cell. The viral LMP1 protein induces the expression and
activity of human DNMTs (Tsai et al. 2002; Tsai et al. 2006), but it
is not known whether it induces hypermethylation of the EBV
genome. We have addressed this issue by the depletion of LMP1
using the RNA interference approach in the RAJI lymphoma cell
line. Knockdown of LMP1 induced DNMT1 and DNMT3B de-
pletion and hypomethylation of particular CpG sites in the EBV
genome (Supplemental Fig. S5).
Finally, as we showed for the other three viral double-strand
DNA methylomes, the EBV DNA methylome was highly adaptable
to the biological and environmental circumstances surrounding
the host cell. The induction of the EBV lytic cycle in a lymphoma
cell line (Akata) upon addition of anti-IgG to the media (Yuan et al.
2006) caused a major change in the EBV DNA methylome, in just
48 h, characterized by the presence of unmethylated transcription
start sites, most likely associated with the newly replicated viral
DNA (Fig. 4F). The viral hypomethylated DNA was accompanied
by the restoration of gene expression of the previously methylated
genes, which matched our expression microarray data (Supple-
mental Fig. S4; Yuan et al. 2006), and as is confirmed here by
Western blot (Fig. 4F). Thus, the dynamic nature of the epi-
genome, exemplified here by the changing EBV DNA methylome,
was further highlighted.
Discussion
Our analysis provides for the first time the complete DNA meth-
ylomes of organisms associated with human disease, the three
double-stranded DNA viruses HPV16, HPV18, and HBV, in addi-
tion to the DNA methylation status of all the transcription start
sites of another double-stranded DNA virus, EBV. These DNA
methylomes have been studied in more than 80 human samples
infected with these viruses at different stages of the disease, and
this large-scale sequencing effort has revealed the dynamic nature
of the epigenome, at least at the level of DNA methylation. One of
the main findings of our study is the progressive increase in the
DNA methylation content in these viruses from asymptomatic
carriers, through benign lesions and pre-malignant disease, to full-
blown human tumors. The DNA methylation of ‘‘foreign’’ (in-
cluding viral) DNA integrated into the human genome has been
studied for decades (Doerfler 2008), but one particularly in-
teresting possibility is that DNA methylation might be a device
to camouflage the virus from our immune system (Tao and
Robertson 2003; Hilleman 2004). A DNA methylation-associated
blockade of viral antigen presentation could be used to evade
immune control. Most interestingly, the use of clinically approved
DNA demethylating agents for the treatment of hematological
malignancies, in addition to restoring the expression of epige-
netically silenced tumor-suppressor genes of the host cell (Bernstein
et al. 2007; Esteller 2007; Feinberg 2007; Jirtle and Skinner 2007;
Jones and Baylin 2007), might also reactivate the immune re-
sponse, thereby enhancing its therapeutic benefits. The DNA
methylomes presented here could be a good starting point for
biomedical researchers who wish to address these questions or to
understand how the viral proteins themselves are able to use our
own DNMTs to favor the establishment of persistent infection.
These issues go beyond basic research and might have a great
impact on public health, since many millions of people in the
world are carriers of these viruses. The potential clinical applica-
tions of these findings include the non-invasive detection of
methylated viral genomes in biological fluids, serum, and blood.
From a geographical location standpoint, we did not observe dif-
ferent DNA methylation profiles, for example, between the NPC
cell line from Southern China and the primary NPCs from
Southern Europe, but larger studies are necessary to address this
issue and other environmental factors. Higher-sequence resolu-
tion might help to discriminate between the scenario wherein
a small number of viral genomes are already methylated among
the large population of unmethylated viral genomes and expand
into the cancerous cells or if there is a methylation change in the
viral genome that drives the carcinogenic change. Above all, the
DNA methylomes obtained here, although owned by very small
organisms, could be an excellent starting point for launching ul-
tra-deep sequencing projects aimed at the complete description of
the human DNA methylome, in a similar way to which microbial
genomes stimulated the race to derive the human genome. Our
viral DNA methylomes, in this regard, could be an excellent proof
of principle for the successful completion of ongoing human
epigenome projects.
Methods
Cell lines and primary tissues
The human cell lines used in this study were obtained from the
American Type Culture Collection (Rockland, MD), the German
Collection of Microorganisms and Cell Cultures (DMSZ,
Braunschweig, Germany), and the Coriell Institute for Medical
Research (Camden, NJ). Cell lines were maintained in the ap-
propriate medium and treated with 5-aza-2-deoxycytidine at
Figure 4. The DNA methylome of EBV. (A) Unsupervised clustering analysis of the EBV DNA methylome in the wild EBV, the B95-8 type EBV, lym-
phoblastoid cell line (BL2126), benign lesions ([RL] reactive lymphadenitis in tonsil and [IM] infectious mononucleosis), post-transplant lymphoproli-
ferative disorder (PTLD), primary lymphomas ([NHL] non-Hodgkin lymphoma, [HL] Hodgkin lymphoma, [BL] Burkitt’s lymphoma), lymphoma cell lines
(Rael, Akata, Raji, Ahh1, Farage, Namalwa), nasopharyngeal primary carcinoma (NPC), and cancer cell line (C666.1). (Red) Methylated and (green)
unmethylated CpG dinucleotides encompassing the corresponding 59-end transcription start sites. (Top) The EBV genome. (B) Methylation-specific PCR
analysis of the EBV FP, WP, and CP 59-end CpG islands in lymphoblastic and Burkitt’s lymphoma cell lines. The presence of a band under the U or M lanes
indicates unmethylated or methylated sequences. In vitro methylated DNA (IVD) is shown as a positive control. (C) Colocalization of the EBV viral genome
determined by FISH and the 5-methylcytosine DNA staining in Akata cells. (D) 59-CpG island methylation-associated silencing of the EBNA2, BRLF1, and
BHRF1-H2H3 genes and the microRNA miR-BHRF1-1 and release of silencing upon the use of a DNA demethylating agent (5-aza-29-deoxycytidine). (Top)
RT-PCRs and Western blots; (middle) bisulfite genomic sequencing; (bottom) q-RT-PCR for miR-BHRF1-1. (E) EBV-immortalized ICF lymphocytes
(DNMT3B defective) demonstrate a hypomethylated EBV genome in comparison to the one observed in DNMT3B-proficient EBV-transformed lym-
phocytes (LCL). (Red) Methylated and (green) unmethylated CpG dinucleotides encompassing the corresponding 59-end transcription start sites. (F) The
induction of the EBV lytic cycle in a lymphoma cell line (Akata) upon addition to the media of anti-IgG caused a massive DNA hypomethylating event in
the EBV-transcription start sites. (Red) Methylated and (green) unmethylated CpG dinucleotides encompassing the corresponding 59-end transcription
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a concentration of 1 mmol/L for 3 d to achieve DNA demethyla-
tion. Cell lines of primary human foreskin keratinocytes trans-
fected with HPV16 or HPV18 were obtained as previously
described (Steenbergen et al. 1996). The EBV lytic cycle was in-
duced in Akata cells upon addition of anti-IgG to the media as
previously described (Yuan et al. 2006). Primary tissues from
normal, pre-malignant, and tumoral samples were all obtained at
the time of the clinically indicated procedures.
Western blot analysis
To study the levels of viral proteins in the cell lines used in the
study, cells were lysed with RSB buffer (10 mmol/L Tris at pH 7.5,
10 mmol/L NaCl, 3 mmol/L MgCl2) in the presence of 1% NP-40
(17) and resuspended in SDS-PAGE loading buffer. Equal amounts
of proteins were separated on 10% SDS-PAGE and transferred to
polyvinylidene difluoride membranes. The membranes were then
hybridized with antibodies against HPV16 E6 (N-17, sc-1584
1:200), HPV16 E7 (ED17, sc-6981 1:200), HPV16 E2 (TVG261,
ab17185: 1:250), Hepatitis B Virus X antigen antibody (3F6-G10,
ab 235, 1:250), Hepatitis B Virus Surface Antigen (Ad/Ay) antibody
(86C, ab20758, 1:200; Abcam), HBV HBcAg (C1-5, sc-23945
1:200), and EBNA2 (DakoCytomation M7004 1:100). The proteins
were detected with the Enhanced Chemiluminescence Plus
Western Blotting Detection System (Amersham Biosciences).
Analysis of CpG methylation status
DNA methylation patterns in the CpG islands were determined by
bisulfite-mediated conversion of unmethylated, but not methylated,
cytosines to uracil as previously described (Clark et al. 1994; Herman
et al. 1996). Bisulfite genomic sequencing of multiple clones was
performed following the detailed protocol described at http://
www.epigenome-noe.net/researchtools/protocol.php?protid=34. In
brief, we first modified the DNA with sodium bisulfite as described
(Herman et al. 1996) and then used Methyl Primer Express software
(Applied Biosystems) to design bisulfite-modified DNA-specific oli-
gonucleotides spanning the whole genomes of the viruses HPV16,
HPV18, and HBV viruses, and all the transcription start sites of the
EBV virus. We next amplified the promoter regions under standard
PCR conditions, cloned the PCR products into pGEM-TEasy Vector
(Promega), randomly selected at least eight colonies per sample, and
performed sequencing using an ABI Prism 3130XL Applied Bio-
systems DNA sequencer. Finally, we analyzed the methylation of
every CpG using Sequencing Analysis 5.2 Software from Applied
Biosystems. DNA methylation at each CpG site was determined in at
least eight clones by bisulfite sequencing of the forward or reverse
strands. For primary samples, we also developed a second analysis
using methylation-specific PCR (MSP) (Herman et al. 1996). A
complete table with all the primers used is provided in Supplemental
Tables S4–S7. To view all the viral DNA methylomes, please go to
http://ubio.bioinfo.cnio.es/Methylyzer/main/index.html.
Quantitative chromatin immunoprecipitation (qChIP) assays
To investigate the presence of E2 protein at the E2-binding sites of
the URR region of the HPV16 genome, chromatin immunopre-
cipitation (ChIP) assays were done as described previously (Bal-
lestar et al. 2003) using the E2 antibody (TVG261, ab17185). Cell
lysates were sonicated for 20 min with 30 sec on-and-off cycles at
the high setting of a Bioruptor (Diagenode) to produce chromatin
fragments of 0.5 kb on average. At least three independent ChIP
experiments were done for each cell line. PCR amplification was
done in 20 mL with specific primers encompassing the URR region.
The sensitivity of PCR amplification was evaluated in serial dilu-
tions of total DNA collected after sonication (input fraction). PCR
conditions for the ChIP assay are available upon request. Negative
controls (no antibody) and input were included for each PCR ex-
periment, and each experiment was carried out in triplicate. For
the real-time PCR reactions, we used the SYBR Green PCR master
mix (Applied Biosystems) and a 7900HT Fast Real-Time PCR sys-
tem (Applied Biosystems). Standard curves were calculated from
serial dilutions (100–0.1 ng) of input genomic DNA. To evaluate
the relative enrichment of target sequences after ChIP, we calcu-
lated the ratios of the signals in the immunoprecipitated DNA
versus input DNA (relative enrichment over input).
Semiquantitative reverse-transcription PCR expression analysis
We reverse-transcribed total RNA (2 mg) treated with DNase I
(Ambion) using oligo(dT) primer with SuperScript II reverse tran-
scriptase (Life Technologies). We used 100 ng of cDNA for PCR
amplification and amplified all of the genes with multiple (20–35)
cycles to determine the appropriate conditions for obtaining
semiquantitative differences in their expression levels. Reverse
transcription-PCR (RT-PCR) primers were designed between dif-
ferent exons to avoid any amplification of DNA. PCRs were done
simultaneously with two sets of primers, with glyceraldehyde-3-
phosphate dehydrogenase as an internal control to ensure cDNA
quality and loading accuracy.
Viral gene expression by quantitative RT-PCR
Total RNA was isolated from CaSki, SiHa, and HeLa cells by TRIzol
(Invitrogen) extraction according to the manufacturer’s instruc-
tions. Then, we transcribed total RNA (2 mg) treated with TURBO
DNA-free (Ambion), using oligo(dT) primer with SuperScript II re-
verse transcriptase (Life Technologies). The gene-specific primer
sequences are available in the Primer Tables. The real-time PCR
reactions typically contained sense and antisense gene-specific
primers (350 nM), 7 mL of SYBR Green PCR Master Mix (Applied
Biosystems), and 2 mL of diluted cDNAs (10 ng/mL) in a total vol-
ume of 14 mL. The reaction was done in an ABI 7900 HT. Glycer-
aldehyde-3-phosphate dehydrogenase expression was used as an
internal control to ensure cDNA quality and loading accuracy.
miR-BHRF1-1 detection by quantitative RT-PCR
Total RNA was isolated from Akata cells and Akata cells treated
with 5-aza-29-deoxycytidine (1 mmol/L for 72 h) by TRIzol (Invi-
trogen), with extraction according to the manufacturer’s instruc-
tions. Trace amounts of unwanted DNA were eliminated using
TURBO DNA-free, from Ambion. We then measured miRNA ex-
pression using quantitative-real-time reverse transcription PCR
(qRT-PCR) using the Ncode SYBR Green ER miRNA qRTPCR Kit
from Invitrogen. Briefly, 1 mg of RNA was polyadenylated follow-
ing the manufacturer’s instructions, and the reverse transcription
was then performed to obtain first-strand cDNA. The gene-specific
primer sequence was identical to the entire mature miRNA se-
quence (see Supplemental Table). The real-time PCR reactions
typically contained gene-specific primer (200 nM), universal qPCR
primer (200 nM), 0.24 mL of ROX Reference Dye, 6 mL of Platinum
SYBR Green qPCR SuperMix-UDG, and 1.2 mL of diluted cDNAs
(1:5) in a total volume of 12 mL. The reaction was done in an ABI
7900 HT. hsa-miR-16 expression was used to normalize ebv-miR-
BHRF1-1 expression levels.
Short interference RNA (siRNA) experiments
Short interference RNA experiments were undertaken as previously
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siRNAs were designed and synthesized by QIAGEN. siRNA for LMP1
(EBV) was provided by Genelink. Scramble siRNA was also pur-
chased by QIAGEN and used as a control. For adherent cells,
transfection was carried out using oligofectamine (Invitrogen)
according to the manufacturer’s specifications. Suspension cells
were transfected by electroporating 107 cells in 0.8 mL of PBS with
10 mg of siRNA at 250 V and 975 mF. The cells were harvested at
specific times for total RNA extraction, and the target genes were
assessed by RT-PCR (primer sequences available upon request).
Fluorescent in situ hybridization (FISH) and
5mC immunodetection
Cell cultures were exposed to colchicine (0.5 mg/mL) for 4 h at 37°C
and harvested routinely. Metaphases were prepared from the im-
mortalized cell lines following a conventional cytogenetic protocol:
Cells were pelleted, gently resuspended in 2–3 mL of 75 mM KCl
pre-warmed to 37°C, and incubated for 15 min at 37°C. Cells were
pelleted and initially resuspended in a residual volume of 100 mL of
freshly made fixation solution (3:1 [v/v] methanol:acetic acid). Up
to 3 mL of fresh fix was added dropwise while the tubes were vor-
texed at low speed. Two more fixation washes in the same fixation
solution were done. To prepare spreads, 100 mL of cells was dropped
onto a pre-cleaned microscope slide, which was dried slowly in
a fume hood and left overnight to age the chromosomes naturally.
Bacterial artificial chromosome (BAC) clones containing the entire
genomic region of the viruses were used to generate the FISH
probes. BAC for HBV16 was kindly provided by Pulivarthi H. Rao
(Texas Children’s Cancer Center, Baylor College of Medicine,
Houston, TX). BAC for HBV was kindly provided by Tian-Hua
Huang (Research Center of Reproductive Medicine, Shantou Uni-
versity Medical College, Shantou 515,041, Guangdong Province,
China). Teru Kanda (Center for Virus Vector Development, Institute
for Genetic Medicine, Hokkaido University, Sapporo 060-0815, Ja-
pan) kindly provided us with BAC for EBV virus. In brief, all BACs
were labeled directly by nick translation according to the manu-
facturer’s specifications using the CGH Nick Translation Reagent Kit
with Spectrum Red dUTP (Abbot Molecular, Inc.). The probes were
blocked with Cot-1 Human DNA (Roche Diagnostic Corp.) to
suppress repetitive sequences. The probe was denatured for 5 min at
96°C and hybridized overnight at 37°C in a humid chamber. After
post-hybridization washes, the cell metaphases were counter-
stained with 49,6-diamidino-2-phenylindole (DAPI II) and included
in a VectaShield mounting medium kit (Vector Laboratories, Inc.)
for chromatin counterstaining and fluorescent protection before
microscopy. Cell images were captured using a CCD camera (Pho-
tometrics SenSys) installed on an Olympus BX microscope con-
nected to a computer running the analysis system CytoVision v. 3.1
Software package (Applied Imaging Corp.). For 5mC immunode-
tection after FISH, cells were treated with 0.5N ClH for 30 min at
37°C and neutralized in Tris-Borate-EDTA buffer for 5 min at room
temperature. Treated samples were blocked in PBS–0.5% BSA for 15
min at room temperature and incubated with mouse monoclonal
antibodies recognizing 5-methylcytidine (a gift from A. Nivelau).
Primary antibodies were detected using Cy2-labeled secondary
antibodies. Confocal optical sections were obtained using a Leica
TCS SP2 microscope (Leica Microsystems) equipped with krypton
and argon lasers. Images were acquired with Leica LCS Lite software
and processed with the publicly available GNU Image Manipula-
tion Program.
Computational analysis
We developed a new Java software package, in the form of a web
server, called ‘‘Methylyzer.’’ It is able to analyze DNA methylation
data obtained from sequences previously modified with bisulfite
and to publish them on the Internet. Data obtained from the
experiments (multiple sequence alignment files) were uploaded to
and analyzed by Methylyzer. Original, new, and lost CpG sites are
located and a methylation value is assigned. Mutations (replace-
ments, insertions, and deletions) are also identified. To navigate
through the genomes of these viruses, we set up a genome browser
(GBrowse) (Stein et al. 2002) that lets the user jump directly to
Methylyzer and visualize the annotations. A set of tracks, which
are very easy to activate, shows the different types of information,
such as ‘‘DNA methylation sequence,’’ ‘‘Genetic sequence,’’
‘‘Transcription start site,’’ ‘‘Gene,’’ ‘‘Exon,’’ and so on. By clicking,
for example, over an annotated ‘‘DNA methylation sequence,’’
one can view the methylation data for the available samples of
a particular amplicon. The samples are represented by a band
colored according to the average level of DNA methylation. It is
possible to click on these bands and the accompanying de-
scription, and this will take the user to another web page with
detailed information for each CpG site of that sample. The in-
formation can be seen in the form of two types of image: those of
the overall bisulfite genomic sequence and those of the bisulfite
genomic sequence of multiple clones. By selecting all or a subset of
the samples, Methylyzer builds images of methylation profiles
that allow the direct comparison of the methylation over the dif-
ferent samples. The data matrix containing the CpGs methylation
profiles for HPV16, HPV18, HBV, and EBV samples were obtained
from Methylyzer. Unsupervised hierarchical clustering (UPGMA)
analyses were carried out applying the City Block Metric (Man-
hattan) and Single Linkage methods.
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